

Herpes Infection Possibly Linked to COVID Vaccine, Study Says + More

By Children's Health Defense

Global Research, April 21, 2021

Children's Health Defense 20 April 2021

Theme: Intelligence, Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Herpes Infection Possibly Linked to COVID-19 Vaccine, Study Says

New York Post reported:

Herpes infections may be a side effect of a <u>COVID-19</u> vaccine, experts have revealed.

Scientists in Israel identified six cases in a new study of patients developing a skin rash known as herpes zoster — or shingles — after receiving the <u>Pfizer</u> vaccine, <u>according to a study in the Rheumatology journal</u>.

Herpes zoster starts off as a small, itchy skin rash, but if left untreated, it could cause nerve damage and pain, the Jerusalem Post reported.

33-Year-Old Woman Hospitalized for 'Mysterious' Paralysis 12 Hours After Pfizer Vaccine

The Defender reported:

A healthy 33-year-old woman in Bethel Park, Pennsylvania, who asked to remain anonymous, experienced paralysis 12 hours after getting her first dose of the Pfizer COVID vaccine and is still hospitalized, WPXI-TV reported.

The Pennsylvania woman said she initially felt fine after being vaccinated, but woke up in the middle of the night with no feeling in her arms or legs.

"It was the scariest thing in the world to go to sleep completely fine (and walking), to wake up 1:30 in the morning and not be able to move at all," the woman said. "I'm literally counting on my daughter to hand me my phone to call to get help."

Paramedics rushed her to the hospital where she was later transferred to the <u>Cleveland Clinic</u> where doctors ran tests to figure out how and why she suffered paralysis. An MRI and spinal tap were clear and blood work all came back negative, ruling out any rare diseases or disorders.

EU Regulators Find 'Possible Link' Between J&J Vaccine and Blood Clots, U.S. Still Investigating

The Defender reported:

The European Medicines Agency (EMA) <u>said Tuesday</u> it found a "possible link" between the Johnson & Johnson (J&J) COVID vaccine and very rare blood clots, but concluded the vaccine's benefits still outweigh the risks.

EMA's safety committee (PRAC) said a warning should be added to the product label, but the blood clot-related disorders should be listed as "very rare" side effects of the vaccine.

J&J had <u>delayed</u> the vaccine's rollout in the EU after concerns about blood clots led U.S. regulators to <u>call for a pause</u>. The company said Tuesday it will <u>resume</u> shipment of the vaccine, distributed under its Janssen subsidiary, in the EU, Norway and Iceland.

In <u>reaching its conclusion</u>, the committee said it took into consideration all currently available evidence including eight reports from the U.S. of serious cases — one of which was fatal — of unusual blood clots. All cases occurred in people under 60, and all occurred within three weeks after vaccination. The majority were women.

Young, Healthy Adults Will Be Deliberately Reinfected With COVID-19 to Boost Vaccine Development

Market Watch reported:

Healthy, young volunteers who have previously had <u>COVID-19</u> will be deliberately exposed to coronavirus for a second time to see how the <u>immune system responds</u>, as part of a new U.K. study.

Researchers at the University of Oxford on Monday launched the <u>"human challenge" trial</u> to investigate what happens when volunteers who have recovered from the coronavirus disease are then reinfected with the virus a second time.

The study, which is funded by the Wellcome Trust, is expected to start in the next few weeks after receiving ethics approval, and could help accelerate the development of new treatments and vaccines against the disease.

Human challenge studies have played a crucial role in the development of treatments for a number of diseases, including malaria, typhoid, cholera and flu.

Mexico President Touts 'No Risks' as He Receives AstraZeneca Vaccine

US News reported:

Mexican President Andres Manuel Lopez Obrador received the <u>AstraZeneca</u> shot against <u>COVID-19</u> on Tuesday, urging trust in vaccines after several countries limited the use of AstraZeneca due to suspected links to rare blood clots.

Lopez Obrador, 67, has said the benefits of getting inoculated outweighed the risks of the low-cost shot, which is a core pillar of Mexico's vaccination strategy.

The Race to Curb the Spread of COVID Vaccine Disinformation

Scientific American reported:

Researchers are launching projects to track and tag vaccine misinformation and disinformation on social media, as well as collecting massive amounts of data to understand the ways in which misinformation, political rhetoric and public policies all interact to influence vaccine uptake across the United States.

Scientists have identified a wide variety of disinformation surrounding <u>COVID-19</u> and vaccines, ranging from conspiracy theories that the pandemic was engineered to control society or boost hospital profits, through to claims that the vaccines are risky and unnecessary.

One research consortium, dubbed the <u>Virality Project</u>, is expanding on strategies pioneered during the election to help inform how platforms such as Twitter and <u>Facebook</u> tackle vaccine disinformation. Created by researchers at multiple US institutions — including Stanford University in California, the University of Washington in Seattle and New York University — the team is working with public-health agencies and <u>social-media companies</u> to identify, track and report disinformation that violates their rules.

With the Competition Struggling, Pfizer's COVID Vaccine Sales Could Hit \$24B This Year

<u>Fierce Pharma reported</u>:

Messenger RNA COVID-19 vaccines are sailing along as viral vector shots encounter setback after setback. How will the recent headlines affect vaccine sales in 2021?

In his weekly notes to investors, Bernstein analyst Ronny Gal offered eyepopping revenue estimates for the mRNA shots from <u>Pfizer</u>-BioNTech and <u>Moderna</u>. He sees the Pfizer team picking up \$24 billion in revenues this year, compared with \$14 billion for Moderna.

Why such a difference? It's about Pfizer and BioNTech's more extensive manufacturing network, Gal wrote to clients Monday.

Johnson & Johnson's COVID-19 Vaccine Adds \$100 Million to Quarterly Sales

The Wall Street Journal reported:

Johnson & Johnson 's COVID-19 vaccine contributed \$100 million to the company's sales growth in the latest quarter, as U.S. health authorities reevaluate the vaccine during a pause amid safety concerns.

As vaccination campaigns help ease the pandemic's severity, Johnson & Johnson's results from its other business lines showed a trend toward normality compared with the tumultuous first months of 2020.

No, We Don't Know If Vaccines Change Your Period

The New York Times reported:

A spate of reports from women stating that their periods changed after they got their <u>coronavirus vaccines</u> has left many women worried that the jab is affecting their cycle.

So far, there's no data linking the vaccines to changes in menstruation. Even if there is a connection, one unusual period is no cause for alarm. There is a long list of triggers that can cause changes to the menstrual cycle, including stress, illness and changes in diet and physical activity.

But that raises the question: If so many things can affect periods, why don't we know more about how these vaccines — or any others — affect menstruation? It's part of a long history of medicine not taking women's bodies seriously.

Adagio Raises \$336 Million to Advance COVID-19 Antibody Treatment

The Boston Globe reported:

Adagio Therapeutics announced on Monday that it has raised \$336 million in additional funding to rapidly advance its COVID-19 antibody therapy to treat and prevent the disease, caused by the coronavirus, as well as illness resulting from new variants.

Last week, the Waltham biotech began recruitment for a global clinical trial to test the drug's efficacy as a treatment for high-risk individuals with mild or moderate COVID-19. The goal: to determine whether a single intramuscular dose could prevent hospitalization and death.

Free Joints for Vaxxed People in DC Today

Washingtonian reported:

A DC group will hand out joints to anyone who can show they've been vaccinated on Tuesday, April 20. DC Marijuana Justice isn't publicizing the locations of "Joints for Jabs" "because we do not want lines or crowding," the group says in a tweet, adding, "If you were already vaccinated, we suggest going back to that location!"

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children's Health Defense

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Children's Health Defense</u>, <u>Children's Health Defense</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Children's Health Defense

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca